Among the clinical inhibitors of poly(ADP-ribose) polymerases (PARPs) and the commonly used PARP research tool compounds, veliparib and niraparib were recently identified as the most selective inhibitors of PARP1 and PARP2. We characterized the potency of A-966492, a PARP inhibitor with a chemical structure similar to veliparib and niraparib, in in vitro inhibition experiments of six PARP family enzymes. We find that the selectivity of A-966492 for PARP1 and PARP2 is intermediate between veliparib and niraparib.
other PARP family enzymes. 5, 6 In order to improve PARP inhibitor based therapies, it is important to understand the individual functions of the diverse PARP family members, and the effect of inhibiting them in a disease relevant context. 6, 7 Thus, research outcomes need to be interpreted in relation to the selectivity of the particular enzyme inhibitor used.
We recently published a selectivity profiling study of PARP and tankyrase inhibitors, 4 and determined that veliparib (ABT-888) and niraparib (MK-4827) had the highest selectivity for PARP1 and PARP2 of the compounds tested. 4 Here, we report a profiling analysis of a similar compound, A-966492, carried out under identical conditions.
Materials and Methods
A-966492 was purchased from Selleck. All other reagents, all proteins and methods were as previously described. 4 Enzymatic inhibition assays were carries out using technical replicates, and repeated 1-4 times.
Results and Discussion
The PARP inhibitor A-966492 has a chemical structure similar to veliparib and niraparib ( Figure 1A) . Figure 1C,D) . The selectivity ratios for PARP1 and PARP2 over PARP3, the next nearest relative, are higher than the corresponding ratios for niraparib, but not as high as for veliparib ( Figure 1E) . We conclude that, of the compounds tested under our conditions, veliparib is the most PARP1 and -2 selective, followed by A-966492, followed by niraparib ( Figure 1F ).
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